A successful therapeutic trial for Amyloidosis
Early results for an antibody designed to clear transthyretin amyloid deposits were presented at a heart failure congress, pointing to a possible new approach.
Newsroom
May 2023
-
-
What is ATTRv amyloidosis?
ATTRv amyloidosis is the hereditary form of ATTR. Its symptoms, its impact on daily life, how it is diagnosed and the treatment options, explained simply.
-
The 4th European ATTR amyloidosis meeting
The 4th European ATTR amyloidosis meeting for patients and physicians takes place on 2 and 3 November 2023, on site and online, with two programmes.
-
What is the status of amyloidosis research?
First described in 1838, amyloidosis remains a young field of research. An overview of what is known about its causes, current treatments and research.